ALK fusions were present in 23 patients in the STS cohort – inflammatory myofibroblastic tumor (n=16), leiomyosarcoma (n=2), rhabdomyosarcoma (n=2), sarcoma NOS (n=2), and myxofibrosarcoma (n=1) –, six patients in uterine sarcoma – uterine leiomyosarcoma (n=2), uterine adenosarcoma (n=1), uterine sarcoma NOS (n=1), and uterine smooth muscle tumor of uncertain malignant potential (n=1) –, and one patient in the GIST cohort. This evidence concerns the gene ALK and sarcoma.